Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Samsung Biologics, a leading contract development and manufacturing organization, announced strong financial results for the second quarter of 2022.
read more
Wednesday, November 06, 2019
Samsung Bioepis has entered into a new commercialization agreement with Biogen for two biosimilar candidates under development by Samsung Bioepis, SB11 (ranibizumab) and SB15 (aflibercept).
read more
Monday, February 11, 2019
Samsung Bioepis announced its expansion in mainland China through a licensing agreement with C-Bridge Capital.
read more
Samsung Biologics, the world’s leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment proteins. Under the ...
read more
Samsung Biologics entered into a strategic partnership with PharmAbcine for the development and manufacturing of PMC-402 pipeline.
read more
Monday, February 24, 2020
Samsung Biologics has been monitoring the COVID-19 situation closely since the initial outbreak in late January and taking proactive measures company-wide to ensure a safe working environment and continuous business operations.
read more
Samsung Biologics, a world-leading contract development and manufacturing organization (CDMO), is launching its new proprietary development technology platforms – S-DUAL™ and DEVELOPICK™ – at this year's BioProcess International Conference and ...
read more
Samsung BioLogics announced today that a third monoclonal antibody Drug Substance has been licensed by the FDA for its second plant.
read more
Wednesday, December 13, 2017
Samsung BioLogics has been licensed by the Europe’s EMA for the first monoclonal antibody Drug Substance at its second plant.
read more
Samsung Biologics announced plans to add mRNA vaccine drug substance (DS) manufacturing capability to the current facility in Songdo, ready for cGMP operations within the earlier part of the year in 2022. mRNA has been the technology of choice for ...
read more
Wednesday, February 17, 2021
Samsung Biologics announced IND clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy.
read more
Wednesday, March 04, 2020
Samsung Biologics and STCube announced a strategic development and manufacturing service agreement for STT-003 antibody, an anti-cancer drug candidate.
read more
Samsung BioLogics and UCB have agreed to an additional drug substance manufacturing deal under which SBL will also produce UCB's anti-tau candidate to treat progressive supranuclear palsy.
read more
SanBio Group and Hitachi Chemical jointly announced that they will manufacture SB623, a proprietary regenerative medicine product under development by SanBio.
read more
Sandoz has announced plans for a joint investment, together with the Austrian federal government, to strengthen the long-term future of integrated antibiotics manufacturing in Europe.
read more